Anti-angiogenic agents, such as endostar (rh-endostatin), bevacizumab (anti-vascular endothelial growth factor A), and ramucirumab (anti-vascular endothelial growth factor R), have been applied for anti-tumor therapies, especially for tumors with advanced clinical stages [15]. Here, VEGFA is linked to neoplasm.